Imdevimab

Imdevimab (REGN10987) is a human monoclonal antibody that targets SARS-CoV-2 virus. Imdevimab can be used in combination with Casirivimab (HY-P99341) to reduce viral load and transiently increases anti-receptor-binding domain IgG titers. Imdevimab maintains most of its neutralization activity against viruses with B.1.1.7, B.1.351 and mink cluster 5 spike proteins[1][2].

Product Specifications

CAS Number

[2415933-40-1]

Product Name Alternative

REGN10987

UNSPSC

12352203

Target

SARS-CoV

Type

Inhibitory Antibodies

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/imdevimab.html

Purity

95.00

Solubility

10 mM in DMSO

Smiles

[Imdevimab]

Molecular Weight

(144.14 kDa)

References & Citations

[1]Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD) : National Institute of Child Health and Human Development; 2006–. Casirivimab. 2022 May 15. |[2]Tada, T., et al., (2021) . Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies. bioRxiv : the preprint server for biology, 2021.02.18.431897.